The discovery that CED-3, the product of a gene necessary for programmed cell death in the nematode Caenorhabditis e/egans, is related to the mammalian cysteine protease interleukin-1 Pconverting enzyme (ICE/caspase-1) has led to intense interest in the role of proteases in apoptosis. It is now clear that at least some members of the caspase (ICE/CED-3) family, which at present includes ten homologues of human origin, are essential components of an evolutionarily conserved pathway of apoptosis.These enzymes appear to be involved in both the initial signaling events and the downstream proteofytic cleavages that result in the apoptotic phenotype. Selective macromolecular and peptide-based inhibitors attenuate apoptosis in whole cells, suggesting that one or more of these enzymes will be suitable targets for therapeutic intervention in diseases resulting from inappropriate cell death.
Historical perspective
In the nematode Caenorhabditis elegans (C. elegans), 131 of the 1090 somatic cells formed during development of an adult undergo programmed cell death (for review, see 1 ) . Elegant genetic studies have established that two genes, ced-3 and ced-4, are required for this cell death, in that deletions or mutations in either gene result in the survival of all of the cells that normally die 2 . Late in 1993, CED-3 was shown to be homologous to interleukin-1 P converting enzyme (ICE/caspase-1) 3 , a cysteine protease originally identified as the enzyme responsible for the processing of the pro-inflammatory cytokine, pro-interleukin-ip (pro-IL-1P) 4 . This finding, together with the observation that a negative regulator of apoptosis in mammals, Bcl-2, is homologous to a repressor of cell death found in C. elegans 5 , strongly suggested that at least somê y, °f tne mechanisms of cell death are evolutionarily conserved, and that Merck Research proteases are important mediators in this process.
loborafonei, When caspase-1 was first purified, cloned and sequenced in 1992 4 ). A unified nomenclature for these enzymes has recently been adopted, using the term 'caspase' as a root for serial names 8 . A phylogenetic analysis of the caspases suggests that these enzymes may be grouped into two, possibly three, subfamilies.
It is now clear that at least some of these enzymes, particularly those most highly related to CED-3, are essential mediators of mammalian apoptosis. First, macromolecular and peptide-based inhibitors of caspases prevent cell death in both in vitro and in vivo models of apoptosis (for examples, see 9 " 12 ). Inhibition is observed in many cell types and in response to diverse stimuli suggesting that these enzymes are components of an essential, conserved cell death mechanism. Second, caspases appear to be responsible for the hydrolysis of several key homeostatic, repair and structural proteins that are cleaved during apoptosis (for review, see 7 ). Third, post-translational activation of several caspases has been shown to correlate with the appearance of the apoptotic phenotype 13 " 15 . Finally, and most compelling, mice deficient in caspase-3 have a defect in the apoptosis that occurs during brain development 16 . These animals die at 1-3 weeks of age and display profound abnormalities of the nervous system. Surprisingly, there are no obvious defects in the development of the other major organs, or in thymocyte apoptosis, even though caspase-3 is normally expressed in these tissues, suggesting that caspases have redundant functions in some cell types.
In contrast to the phenotype observed with caspase-3 deficient animals, mice unable to produce caspase-1 have no major defects in apoptosis, indicating that this family member does not play a central, non-redundant role in this process 17 -18 . However, these mice do have a defect in IL-ip production, and are resistant to LPS-induced endotoxic shock, confirming a role for this protease in inflammation. Taken together, studies to date indicate that caspases have diverse functions, with members of this family playing essential roles in both inflammation and apoptosis.
Distinguishing properties of caspases
The two best characterized members of the caspase family are caspase-1 and caspase-3, the latter being the human enzyme most closely related to CED-3. Both have been purified from natural sources, cloned, and their structures determined by X-ray crystallography . The results of these studies, together with a comparison of the primary sequences of all of known caspases, suggest that the following are distinguishing structural and catalytic properties of these enzymes.
First, the mature enzymes are heterodimers composed of two subunits with approximate molecular weights of 10 and 20kDa. The two subunits are intimately associated to form a single catalytic domain in which both contribute key residues to the active site. In analogy with other cysteine proteases, the active site contains a catalytic diad composed of a cysteine sulphydryl group in close proximity to a histidine imidazole group, which is presumed to function as a general acid/base during substrate hydrolysis. The oxyanion of the tetrahedral intermediates formed during catalysis appears to be stabilized through hydrogen bonding interactions in what is typically referred to as an 'oxyanion hole'. In the crystal structures of caspase-1 and caspase-3 in complex with peptide-based inhibitors, two heterodimers associate to form a tetramer, and it has been proposed that this is the active form of the enzyme in solution.
Second, all of these enzymes appear to have a near absolute requirement for aspartic acid in the P a position in both macromolecular and peptide substrates. Caspase-1 catalyzes the cleavage of the inactive 31kDa human pro-IL-lp at . The crystal structures of caspase-1 and caspase-3 define the four residues that are responsible for this selective interaction (Arg 179 , Gln 2 83, Arg^j, Ser 347 ), and all of these are conserved among all known family members. It is intriguing that these cysteine proteases, and the cytotoxic lymphocytederived serine protease granzyme B, which also functions in apoptosis, are the only mammalian proteases known to have this specificity.
Third, in contrast to the apparent similarities between the S^ subsites of known caspases, the chemical nature and geometry of other subsites (most notably S 4 ) do not appear to be conserved among all caspases, providing a rationale for the distinct macromolecular specificities, and hence functions, of these enzymes. For example, studies with both peptide and protein substrates indicate that caspase-1 prefers large, hydrophobic amino acids in the P 4 position, while in caspase-3 all of the endogenous substrates that have been identified to date contain an aspartic acid in this position. This P 4 aspartic acid appears to be required for efficient hydrolysis by caspase-3, in that replacement of this residue with any other amino acid results in > 100-fold decrease in k^/Kn,. A comparison of S 4 in the crystal structures of caspases 1 and 3 reveals profound differences in both the geometry and the chemical composition of this subsite that explain their distinct specificities. For example, S 4 in caspase-1 is a shallow depression that easily accommodates a hydrophobic side chain. In contrast, in caspase-3 S 4 is a narrow pocket containing several side chains that serve to stabilize the aspartic acid.
Many of the residues in caspase-3 that are responsible for its stringent specificity for Asp in S 4 are conserved among closely related homologs, suggesting that at least some members of the caspase family will have similar specificities. This is consistent with the hypothesis that some of these enzyme have redundant functions.
Finally, as shown in Figure 1 , all of these enzymes are synthesized as proenzymes from which both subunits of the heterodimer are derived by proteolytic processing 4 -11 . The genes for these proenzymes also encode an N-terminal peptide of variable length (approximately 3-13 kDa), and in some cases a linker peptide between the two subunits, both of which are removed during proteolytic activation. Both the large and small subunits of the heterodimer are flanked by Asp-X bonds, suggesting that activation is either autocatalytic, or mediated by an enzyme with a similar specificity. These alternate mechanisms for activation are considered below.
Inhibitors of caspases
Several macromolecular and peptide-based inhibitors of caspases have been identified and used to secure a role for at least some of these enzyme in apoptosis. Two naturally occurring protein inhibitors have been described. Cytokine response modifier A (CrmA) is a 38 kDa serpin from cowpox virus that appears to facilitate infection through both inhibition of the host inflammatory response, and inhibition of apoptosis 24 . CrmA has been evaluated as an inhibitor of both caspase-1 and caspase-3, and found to exhibit very different potencies against the two enzymes 11 ' 25 . It is a potent inhibitor of caspase-1 (K,=4 pM, k on =1.7 x 10 7 M^s" 1 ) and a weak caspase-3 inhibitor (K, > 100 nM, k^, <1 x 10 4 M^s" 1 ). The poor inhibition observed with caspase-3 can be explained by the stringent specificity of this enzyme for Asp in S 4 , as CrmA requires recognition at the sequence LVAD for inhibition. The target(s) for CrmA inhibition during apoptosis has not been established, but it is likely that its mechanism involves inhibition of these proteases, because, as mentioned above, cleavage after Asp is uncommon among proteases.
Another viral gene product, a 35 kDa protein from baculovirus (p35), also appears to attenuate apoptosis through inhibition of the caspases. Expression of p35 has been shown to prevent cell death in insect cells, C. elegans, and in mammalian systems of apoptosis 26 . . Reversible inhibitors include aldehydes, mtriles and ketones. Irreversible inhibitors are of the general structure Peptide-CO-CH 2 -X, where X is a halide ion (chloromethylketones, fluoromethylketones), -N 2 (diazomethylketones), -OCOR ((acyloxy)methylketones), or -OR (a-(pyrazoloxy)methylketones and (phosphinyloxy)methylketones).
The peptide moiety of these inhibitors determines their selectivity for particular caspases. For example, the tetrapeptide aldehyde based on the pro-IL-ip cleavage site, Ac-YVAD-CHO, is a potent inhibitor of caspase-1 (K,=0.76nM), and a weak inhibitor of caspase-3 (K^lOjOOOnM) 11 . This reflects the inability of caspase-3 to tolerate hydrophobic residues in S 4 . In contrast, the aldehyde containing the PARP cleavage site, Ac-DEVD-CHO, is a relatively potent inhibitor of both caspase-1 and caspase-3, with a 49-fold preference for caspase-3 (K, iCaspase .3=0.35 nM, K 1)Caspase _i=17 nM) 7 '. The reduced selectivity of this inhibitor is an indication of the promiscuity of the S 4 subsite of caspase-1, which prefers hydrophobic amino acids, but accepts many others (including aspartic acid).
As mentioned above, these aldehyde inhibitors, and several other peptide-based inhibitors of these enzymes, have been shown to be effective at preventing apoptosis in diverse models of apoptosis. However, these compounds are not useful as probes of biological function for particular family members because extremely high concentrations (> 10 uM) are generally required for efficacy, presumably because of poor cell penetration.
Roles in apoptosis
Current evidence suggests that caspases are essential components of a proteolytic cascade that is triggered in response to a death stimulus, having roles in both the regulation and execution stages of apoptosis. For example, in apoptosis induced by Fas ligand, caspase-8 has been implicated in upstream signaling events, while caspase-3 and closely related homologs appear to be involved in the effector phase of apoptosis. The phenotype of caspase-3 deficient mice strongly suggests that at least some caspases have redundant functions within mammalian cells, presumably in both stages of apoptosis. The proposed biochemical roles of these enzymes in apoptosis are described in detail below, and summarized in a putative model for Fas-induced apoptosis (Fig. 2) .
Cleavage of homeostatic and structural proteins
The identification of potential endogenous substrates for the caspases has provided important clues to their molecular role(s) in apoptosis.
Proteins that are known to be cleaved during apoptosis generally fall into two major groups: (i) catalytic proteins functioning in homeostatic pathways; and (ii) those involved in organization and maintenance of cell structure (for review, see 7 )
. In every case, hydrolysis occurs after aspartic acid, suggesting the involvement of a caspase, or an enzyme with similar specificity (e.g. granzyme B).
As summarized in Table 1 , several proteins that are believed to be involved in maintenance of normal cell function and repair processes are cleaved during apoptosis. It has been suggested that crippling of these pathways may be a fundamental feature of apoptosis, to ensure the rapid irreversibility of this process 31 . For example, poly (ADP-ribose) polymerase (PARP) and the catalytic subunit of DNA-dependent protein kinase (DNA-PK^) have been implicated in DNA repair pathways. Proteolytic inactivation of these proteins may be necessary for the efficient degradation of DNA that is observed during apoptosis.
All of these homeostatic proteins appear to be cleaved during apoptosis at a DXXD motif. Several observations suggest that caspase-3 and/or closely related homologs are responsible for these proteolytic events. First, as discussed above, caspase-3 has a near absolute characteristics of these proteolytic events in extracts from apoptotic cells are consistent with those observed with purified caspase-3 in vitro 31 . Evidence that family members other than caspase-3 also have the ability to hydrolyze PARP in vivo has been obtained in caspase-3-deficient mice, where cleavage of PARP was observed in thymocytes induced to undergo apoptosis 16 . Structural proteins cleaved during apoptosis include cytoskeletal proteins (fodnn, actin, Gas2), and proteins involved in maintaining nuclear structure (NuMA, lamins). The cleavage of these and other, as yet undefined, proteins may be responsible for many of the observed biochemical and morphologic features that are characteristic of the apoptotic cell, such as surface blebbing and nuclear condensation. The particular caspases responsible for these cleavages have not been firmly established. Unlike the homeostatic proteins described above, in general, the structural proteins do not appear to be cleaved at a DXXD motif, suggesting the involvement of a caspase (or caspases) other than caspase-3. Consistent with this conclusion, lamin A is efficiently cleaved by caspase-6 in vitro 15 ' 32 .
Regulation of apoptosis by caspases
As noted above, all caspases are synthesized as proenzymes that required proteolytic activation at Asp-X sites to produce the mature, catalytically active heterodimers. It follows that activation is either autocatalytic, or mediated by an enzyme with a similar specificity. The results from several independent investigations support the hypothesis that at least some of these enzymes participate as upstream mediators in a proteolytic cascade that serves to amplify the death signal. First and most compelling, caspase-8 has been shown to be physically associated with the Fas receptor complex, via an interaction with the adapter protein, FADD/MORT1 33 ' 34 . It appears that this interaction is mediated through dimerization of the death effector domain (DED) of FADD/MORT1, and an analogous domain in the N-terminal peptide of the caspase-8 proenzyme that is removed during activation. Although the mechanism of this activation has not been established, this finding strongly suggests that caspase-8 participates in the signaling activity of the receptor complex during Fas-mediated cell death, and represents the most upstream component in a caspase cascade. It is anticipated that caspase-10, which also contains a DED in its prodomain, will have an analogous function 35 . These findings suggest a rationale for the variable length of the prodomain in caspases. Recently, it has been shown that the prodomain of caspase-1 is absolutely required for its dimerization and autoactivation 36 . It is tempting to speculate that those caspases with long prodomains have a regulatory role in apoptosis, functioning to activate the caspases with short prodomains which may be unable to dimerize and autoactivate in cells.
Further evidence for a proteolytic cascade comes from investigations into the target(s) of inhibition of apoptosis by both macromolecular and peptide-based inhibitors, which have been shown to prevent activation of those caspases implicated in the effector phase of apoptosis. For example, expression of CrmA in a model of Fas-induced apoptosis prevents activation of both caspase-3 and caspase-7 37 . Similar results are observed with the peptide-based caspase inhibitor, Z-VAD-fluoromethylketone 38 . These results suggest that the target(s) of these inhibitors is a caspase upstream of the effector caspases. Studies of apoptosis induced by Fas ligand suggest this upstream protease has a specificity that is clearly distinct from that of at least some of the downstream enzymes , leading to speculation that this is one of its primary roles in cytotoxic lymphocytemediated cell death. By analogy, it is reasonable to conclude that proteases are also required for the activation of these caspases in other apoptotic systems. Taken together, the findings summarized here strongly support the hypothesis that proteolytic cascades are involved in at least some of the apoptosis that occurs in vivo.
Challenges for future research
The frenetic pace of research aimed at understanding the roles of proteases in apoptosis has quickly led to important insights into the biochemical pathways that these enzymes govern. It is clear that these proteases play a central role in most, if not all, of the apoptosis that occurs in mammals. It is also clear that inhibitors of these enzymes, that are likely to be selective for this protease family, prevent the appearance of the morphological features that are characteristic of the apoptotic phenotype, suggesting that these enzymes may be suitable targets for therapeutic intervention. The finding that some of these proteases arc involved in the signaling events, in at least some cell types, suggests that intervention can occur before the cell is irreversibly committed to death. The phenotype of caspase-3 deficient mice suggests that this enzyme, in particular, may be an appropriate target for therapeutic intervention in diseases resulting from inappropriate apoptosis in neuronal tissues.
Notwithstanding, several obstacles must be overcome to achieve a therapeutic benefit through inhibition, or activation, of these proteases. First, more studies are required to determine the identities of the caspases involved in mechanisms of cell death in different cell types, and in response to diverse stimuli. In this regard, the phenotype of caspase-3 deficient mice is enlightening, and provocative. Results obtained with these animals strongly suggest that at least some of these enzymes, presumably closely related homologs, have redundant functions. However, it is also clear from these studies that caspase-3 plays a nonredundant role in the apoptosis that occurs during brain development, despite the observation that closely related homologs (caspases 6 and 7) are expressed in neuronal tissues. A better understanding of the key proteases present in different tissues, their functions in these tissues, and their regulation, is required to identify suitable targets for therapeutic modulation.
Second, once an appropriate target in the tissue of interest is identified, selective inhibition or activation of a single caspase may be difficult to achieve. The conclusion that some of these enzymes have redundant functions also implies that their active sites are highly related. Hopefully, structural studies of the various homologs will reveal opportunities for the design of selective inhibitors. Alternatively, there may be significant advances in our ability to deliver drugs to specific tissues. Selective inhibition is expected to be essential for treatment of chronic diseases. In contrast, in cases where premature cell death results from acute injuries (e.g. stroke, ischemia), selective inhibition is probably not as important.
Finally, to attenuate apoptosis in vivo, potent, non-peptide inhibitors must be identified that are stable, bioavailable, and able to penetrate cells. The latter is a significant challenge, particularly given that the active sites of these enzymes were designed to accommodate one or more negatively charged entities. In general, charged molecules do not effectively penetrate cells. Consideration of caspase-3 as a potential target for treatment of diseases resulting from excessive neuronal apoptosis presents an even more formidable challenge, as in this case inhibitors will also have to penetrate the blood brain barrier.
